Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma

Study identifier:ACE-LY-003

ClinicalTrials.gov identifier:NCT02180711

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma

Medical condition

Non Hodgkin Lymphoma

Phase

Phase 1/2

Healthy volunteers

No

Study drug

acalabrutinib, rituximab (IV), Lenalidomide

Sex

All

Actual Enrollment

113

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 29 Dec 2014
Primary Completion Date: 25 Aug 2023
Estimated Study Completion Date: 29 Dec 2028

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AcertaPharma

Sponsors

AcertaPharma

Collaborators

AstraZeneca

Inclusion and exclusion criteria